Pharmacokinetics, Mass Balance, Safety, and Tolerability of Obeldesivir in Healthy Participants
Clinical Pharmacology & Therapeutics · 2024-11 · 116 (5) · 1231-1239
DOI: 10.1002/cpt.3337 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift Clinical Pharmacology & Therapeutics, online erschienen am 28.06.2024. Verfasst von Olena Anoshchenko und 18 weiteren Autor:innen. Beteiligte Einrichtung: Gilead Sciences, Inc., Foster City, California, USA. Hauptthemen laut MEDLINE: Antiviral Agents, Healthy Volunteers. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Gilead Sciences, Inc., Gilead Sciences.
Abstract (Originalsprache)
There is an unmet need for safe and efficacious oral therapies for COVID‐19 with low potential for drug–drug interactions. Obeldesivir is an orally administered nucleoside prodrug that has shown antiviral potency in nonclinical studies against SARS‐CoV‐2 and its circulating variants. Obeldesivir is metabolized to the active nucleoside triphosphate (GS‐443902), which acts as an inhibitor of the SARS‐CoV‐2 RNA‐dependent RNA polymerase, thereby inhibiting viral RNA synthesis. Here, we report the safety, tolerability, and pharmacokinetics from a first‐in‐human, randomized, placebo‐controlled, phase I study following oral administration of obeldesivir and a phase I, open‐label absorption, distribution, metabolism, and excretion study following oral administration of [ 14 C]‐obeldesivir. Overall, obeldesivir was safe and well tolerated at single and multiple doses between 100 and 1,600 mg, with low potential for QT prolongation as assessed by QT‐concentration analysis. The exposures to GS‐441524 increased dose proportionally in the 100–900‐mg dose range. GS‐441524 accumulated by 35% after twice‐daily and 12% after once‐daily dosing for 5 days. Dose‐proportional increases in the intracellular concentration of GS‐443902 were also observed in peripheral blood mononuclar cells. Plasma exposure of GS‐441524 was not significantly altered by food intake. Following oral administration of [ 14 C]‐obeldesivir (500 mg; 100 μCi), the mean cumulative [ 14 C]‐dose recovery was 90.7% with 58.5% in urine and 32.2% in feces. GS‐441524 was the predominant plasma component (90% of 14 C‐area under the concentration–time curve) and was primarily eliminated via renal excretion. Collectively, data from these studies support selection of the obeldesivir 350 mg twice‐daily dosing regimen for further evaluation in phase III studies for COVID‐19.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Gilead Sciences, Inc., Foster City, California, USA.
ORCID-Profile: Olena Anoshchenko, Mazin Abdelghany, Amos Lichtman, Henry Chen, Naveed A Shaik, Raju Subramanian, Robert H Hyland, Deqing Xiao, Luzelena Caro, Helen Winter, Joe Llewellyn, Rita Humeniuk
Förderung
- Gilead Sciences, Inc.
- Gilead Sciences
Zitieren
APA
Anoshchenko, O., Abdelghany, M., Lichtman, A., Duan, R., Chen, H., Shaik, N. A., Peng, C. C., Yue, Q., Subramanian, R., Hyland, R. H., Davies, S., Castellanos, K., Mak, L., Shen, G., Xiao, D., Caro, L., Winter, H., Llewellyn, J., & Humeniuk, R. (2024). Pharmacokinetics, Mass Balance, Safety, and Tolerability of Obeldesivir in Healthy Participants. Clinical Pharmacology & Therapeutics, 116(5), 1231-1239. https://doi.org/10.1002/cpt.3337
Vancouver
Anoshchenko O, Abdelghany M, Lichtman A, Duan R, Chen H, Shaik NA, et al. Pharmacokinetics, Mass Balance, Safety, and Tolerability of Obeldesivir in Healthy Participants. Clinical Pharmacology & Therapeutics. 2024;116(5):1231-1239. doi:10.1002/cpt.3337
BibTeX
@article{Anoshchenko2024,
author = {Anoshchenko, Olena and Abdelghany, Mazin and Lichtman, Amos and Duan, Ran and Chen, Henry and Shaik, Naveed A and Peng, Chi-Chi and Yue, Qin and Subramanian, Raju and Hyland, Robert H and Davies, Santosh and Castellanos, Keelin and Mak, Lily and Shen, Gong and Xiao, Deqing and Caro, Luzelena and Winter, Helen and Llewellyn, Joe and Humeniuk, Rita},
title = {Pharmacokinetics, Mass Balance, Safety, and Tolerability of Obeldesivir in Healthy Participants},
journal = {Clinical Pharmacology & Therapeutics},
year = {2024},
volume = {116},
number = {5},
pages = {1231--1239},
doi = {10.1002/cpt.3337}
}
EUVIMED